Simulations Plus Reports 8% Revenue Growth in Q2
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy SLP?
Source: Yahoo Finance
- Revenue Growth: Simulations Plus reported $24.3 million in revenue for Q2, an 8% increase, indicating robust growth in both software and services segments, which enhances the company's competitive position in the market.
- Adjusted EBITDA Performance: The company achieved an adjusted EBITDA of $8.7 million, reflecting a strong 36% margin, showcasing operational efficiency and profitability that boosts investor confidence.
- Strong Cash Position: At the end of the quarter, the company had $41.8 million in cash and short-term investments with no debt, indicating strong financial health that supports future strategic investments and growth.
- Decline in Clinical Operations Revenue: Despite overall strong performance, clinical operations revenue plummeted by 54%, which could impact the company's future revenue outlook and reflects uncertainty in the market environment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLP
Wall Street analysts forecast SLP stock price to rise
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 12.990
Low
19.00
Averages
19.00
High
19.00
Current: 12.990
Low
19.00
Averages
19.00
High
19.00
About SLP
Simulations Plus, Inc. is a provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. It operates through two segments: software and services. The Company’s business units include cheminformatics, physiologically based pharmacokinetics, clinical pharmacology and pharmacometrics, quantitative systems pharmacology, adaptive learning & insights and medical communications. The Company operates in biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry. It delivers simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Its cutting-edge technology is licensed and utilized by pharmaceutical, biotechnology, and regulatory agencies worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Simulations Plus Reports Q2 Adjusted EPS of $0.35, Beating IBES Estimate of $0.20
Economic Indicators: The latest simulations indicate a Q2 adjusted EPS of USD 0.35, which is higher than the previous estimate of USD 0.2.
Market Expectations: The revised EPS suggests a more optimistic outlook for the company's financial performance compared to earlier predictions.
See More
Simulations Plus Announces Financial Results for Second Quarter of Fiscal Year 2026
Financial Performance: Simulations Plus reported its financial results for the second quarter of fiscal 2026, highlighting key metrics and performance indicators.
Revenue Growth: The company experienced notable revenue growth compared to previous quarters, reflecting strong demand for its simulation software products.
See More
Market Remains Cautious as Oil Approaches $100 Amid Inflation Concerns
- Market Dynamics: Stock futures are essentially flat, reflecting a cautious market waiting for confirmation, with momentum from earlier in the week fading as investors remain on the sidelines regarding future trends.
- Oil Price Movement: Oil prices are creeping higher again, hovering near the $100 per barrel level, primarily due to doubts about the durability of the ceasefire and ongoing disruptions in the Strait of Hormuz, indicating persistent inflationary pressures.
- CPI Report Impact: The Consumer Price Index (CPI) report showed the sharpest year-over-year price increases for consumers in nearly four years, largely driven by the recent energy shock, and despite a pause in fighting, oil flows remain constrained and supply chains are still disrupted.
- Stock Market Performance: In pre-market trading, S&P 500 futures rose 0.14%, Nasdaq futures rose 0.21%, and Dow futures rose 0.02%, reflecting a cautiously optimistic sentiment in the market regarding future developments.
See More
Simulations Plus Reports Strong Q2 Results Despite Guidance Cut
- Revenue Growth: Simulations Plus reported Q2 revenue of $24.3 million, an 8% year-over-year increase, with software revenue rising 9% to $14.6 million and services revenue also increasing by 8%, indicating sustained growth potential in the healthcare tech sector.
- Net Income Improvement: Non-GAAP net income rose 13% to over $7 million, or $0.35 per share, exceeding analyst expectations of $0.31, demonstrating enhanced profitability for the company.
- Guidance Adjustment: Despite strong performance, the company lowered its full-year adjusted net income guidance to $0.75 to $0.85 per share from a previous forecast of $1.03 to $1.10, primarily due to a higher effective tax rate, which may dampen investor sentiment.
- Market Reaction: Although the market reacted lukewarm with a mere 0.4% increase in stock price, analysts believe the company's robust performance and ongoing growth momentum in both software and services make it a worthwhile investment.
See More
Simulations Plus Q2 Earnings Beat Expectations Despite Guidance Cut
- Significant Revenue Growth: Simulations Plus reported $24.3 million in revenue for Q2 2026, an 8% year-over-year increase, with software revenue rising 9% to $14.6 million and service revenue also increasing by 8%, indicating strong performance in the healthcare tech sector.
- Profit Exceeds Expectations: The non-GAAP net income rose 13% to $7 million, or $0.35 per share, surpassing analyst expectations of $0.31, reflecting an improvement in the company's profitability.
- Full-Year Guidance Cut: Despite the strong Q2 results, Simulations Plus lowered its full-year adjusted net income forecast to $0.75 to $0.85 per share, down from the previous estimate of $1.03 to $1.10, primarily due to a higher effective tax rate.
- Mild Market Reaction: Although the company exceeded expectations, its stock only rose 0.4%, indicating investor uncertainty regarding future profitability, which may affect short-term investor confidence.
See More
Simulations Plus Reports Strong Q2 Results Despite Guidance Cut
- Revenue Growth: Simulations Plus reported Q2 revenue of $24.3 million, an 8% year-over-year increase, with software revenue rising 9% to $14.6 million and services revenue also increasing by 8%, indicating strong demand and market recognition in the healthcare tech sector.
- Profit Improvement: Non-GAAP net income increased by 13% to over $7 million, or $0.35 per share, surpassing analyst expectations of $0.31, reflecting the company's robust profitability amidst growth.
- Guidance Cut: Despite solid performance, Simulations Plus lowered its full-year adjusted net income guidance to $0.75 to $0.85 per share from a previous forecast of $1.03 to $1.10, primarily due to a higher effective tax rate, which may dampen investor confidence.
- Market Reaction: Although the company exceeded expectations, its stock only rose by 0.4%, indicating market uncertainty regarding future profitability, prompting investors to carefully assess its long-term investment value.
See More
Simulations Plus Reports Q2 Adjusted EPS of $0.35, Beating IBES Estimate of $0.20
Economic Indicators: The latest simulations indicate a Q2 adjusted EPS of USD 0.35, which is higher than the previous estimate of USD 0.2.
Market Expectations: The revised EPS suggests a more optimistic outlook for the company's financial performance compared to earlier predictions.
See More
Simulations Plus Announces Financial Results for Second Quarter of Fiscal Year 2026
Financial Performance: Simulations Plus reported its financial results for the second quarter of fiscal 2026, highlighting key metrics and performance indicators.
Revenue Growth: The company experienced notable revenue growth compared to previous quarters, reflecting strong demand for its simulation software products.
See More
Market Remains Cautious as Oil Approaches $100 Amid Inflation Concerns
- Market Dynamics: Stock futures are essentially flat, reflecting a cautious market waiting for confirmation, with momentum from earlier in the week fading as investors remain on the sidelines regarding future trends.
- Oil Price Movement: Oil prices are creeping higher again, hovering near the $100 per barrel level, primarily due to doubts about the durability of the ceasefire and ongoing disruptions in the Strait of Hormuz, indicating persistent inflationary pressures.
- CPI Report Impact: The Consumer Price Index (CPI) report showed the sharpest year-over-year price increases for consumers in nearly four years, largely driven by the recent energy shock, and despite a pause in fighting, oil flows remain constrained and supply chains are still disrupted.
- Stock Market Performance: In pre-market trading, S&P 500 futures rose 0.14%, Nasdaq futures rose 0.21%, and Dow futures rose 0.02%, reflecting a cautiously optimistic sentiment in the market regarding future developments.
See More
Simulations Plus Reports Strong Q2 Results Despite Guidance Cut
- Revenue Growth: Simulations Plus reported Q2 revenue of $24.3 million, an 8% year-over-year increase, with software revenue rising 9% to $14.6 million and services revenue also increasing by 8%, indicating sustained growth potential in the healthcare tech sector.
- Net Income Improvement: Non-GAAP net income rose 13% to over $7 million, or $0.35 per share, exceeding analyst expectations of $0.31, demonstrating enhanced profitability for the company.
- Guidance Adjustment: Despite strong performance, the company lowered its full-year adjusted net income guidance to $0.75 to $0.85 per share from a previous forecast of $1.03 to $1.10, primarily due to a higher effective tax rate, which may dampen investor sentiment.
- Market Reaction: Although the market reacted lukewarm with a mere 0.4% increase in stock price, analysts believe the company's robust performance and ongoing growth momentum in both software and services make it a worthwhile investment.
See More
Simulations Plus Q2 Earnings Beat Expectations Despite Guidance Cut
- Significant Revenue Growth: Simulations Plus reported $24.3 million in revenue for Q2 2026, an 8% year-over-year increase, with software revenue rising 9% to $14.6 million and service revenue also increasing by 8%, indicating strong performance in the healthcare tech sector.
- Profit Exceeds Expectations: The non-GAAP net income rose 13% to $7 million, or $0.35 per share, surpassing analyst expectations of $0.31, reflecting an improvement in the company's profitability.
- Full-Year Guidance Cut: Despite the strong Q2 results, Simulations Plus lowered its full-year adjusted net income forecast to $0.75 to $0.85 per share, down from the previous estimate of $1.03 to $1.10, primarily due to a higher effective tax rate.
- Mild Market Reaction: Although the company exceeded expectations, its stock only rose 0.4%, indicating investor uncertainty regarding future profitability, which may affect short-term investor confidence.
See More
Simulations Plus Reports Strong Q2 Results Despite Guidance Cut
- Revenue Growth: Simulations Plus reported Q2 revenue of $24.3 million, an 8% year-over-year increase, with software revenue rising 9% to $14.6 million and services revenue also increasing by 8%, indicating strong demand and market recognition in the healthcare tech sector.
- Profit Improvement: Non-GAAP net income increased by 13% to over $7 million, or $0.35 per share, surpassing analyst expectations of $0.31, reflecting the company's robust profitability amidst growth.
- Guidance Cut: Despite solid performance, Simulations Plus lowered its full-year adjusted net income guidance to $0.75 to $0.85 per share from a previous forecast of $1.03 to $1.10, primarily due to a higher effective tax rate, which may dampen investor confidence.
- Market Reaction: Although the company exceeded expectations, its stock only rose by 0.4%, indicating market uncertainty regarding future profitability, prompting investors to carefully assess its long-term investment value.
See More
